Reviewing Dextera Surgical (DXTR) and GenMark Diagnostics (GNMK)

Dextera Surgical (NASDAQ: DXTR) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Insider and Institutional Ownership

7.8% of Dextera Surgical shares are owned by institutional investors. 10.4% of Dextera Surgical shares are owned by insiders. Comparatively, 7.5% of GenMark Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Dextera Surgical and GenMark Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dextera Surgical -441.88% N/A -169.94%
GenMark Diagnostics -111.96% -109.89% -60.26%

Valuation and Earnings

This table compares Dextera Surgical and GenMark Diagnostics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Dextera Surgical $3.42 million 1.53 -$13.98 million ($1.75) -0.17
GenMark Diagnostics $50.59 million 9.64 -$49.93 million ($1.21) -7.37

Dextera Surgical has higher revenue, but lower earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Dextera Surgical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Dextera Surgical has a beta of -1.1, indicating that its share price is 210% less volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Dextera Surgical and GenMark Diagnostics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dextera Surgical 0 0 2 0 3.00
GenMark Diagnostics 0 0 4 0 3.00

Dextera Surgical presently has a consensus price target of $0.75, suggesting a potential upside of 155.02%. GenMark Diagnostics has a consensus price target of $14.75, suggesting a potential upside of 65.36%. Given Dextera Surgical’s higher possible upside, analysts plainly believe Dextera Surgical is more favorable than GenMark Diagnostics.

Summary

GenMark Diagnostics beats Dextera Surgical on 7 of the 12 factors compared between the two stocks.

Dextera Surgical Company Profile

Dextera Surgical Inc., formerly Cardica, Inc., designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its MicroCutter 5/80 is a commercially available cartridge-based microcutter device with approximately five millimeter shaft diameter, over 80 degrees of articulation, and an approximately 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union (EU) for a range of indications for use. It designs, manufactures and markets automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump coronary artery bypass graft procedures and these products include the C-Port xA system, the C-Port Flex A system and the PAS-Port Proximal Anastomosis System.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Receive News & Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply